Does Wellcare Cover Ozempic?
The verdict
Conditional on most plans
Wellcare covers Ozempic for type 2 diabetes with prior authorization under Medicare Part D and Medicaid — it is not covered for off-label weight-loss use under any Wellcare line of business. As a Centene Medicare Part D and Medicaid managed-care operation, Wellcare's readership is overwhelmingly Medicare beneficiaries and low-income enrollees for whom the $2,100 Part D OOP cap and the IRA price track are the operative cost levers.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Wellcare using your member ID.
Key facts
Ozempic is FDA-approved for type 2 diabetes glycemic control and cardiovascular risk reduction in T2D patients — not for weight loss.
FDA drug labeling (semaglutide injection)
The IRA Maximum Fair Price for semaglutide under Medicare is $274 per 30-day supply, effective January 1, 2027 — a 71% discount off the CY2024 list price of ~$959.
CMS, IRA Drug Price Negotiation Program, 2024
The 2026 Medicare Part D out-of-pocket cap is $2,100, limiting maximum annual beneficiary exposure for covered drugs including Ozempic.
CMS, Medicare Part D Redesign, Inflation Reduction Act
Medicare vs. commercial coverage
Whether Wellcare covers Ozempic depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D: Ozempic is listed on the Wellcare plan drug list for type 2 diabetes with prior authorization. PA requires a documented T2D diagnosis plus evidence of metformin step-therapy (or documented intolerance/contraindication); some Wellcare Part D plans also require a prior sulfonylurea or other oral-agent trial. The 2026 Part D out-of-pocket cap of $2,100 limits annual beneficiary exposure. Medicare beneficiaries cannot use the NovoCare $25 savings card — federal anti-kickback rules exclude Medicare and Medicaid enrollees. The IRA Maximum Fair Price for semaglutide (Ozempic/Rybelsus/Wegovy) is $274 per 30-day supply, effective January 1, 2027, representing a 71% discount off the CY2024 list price. A separate Trump-administration most-favored-nation track targets $245/month with a $50 beneficiary copay; both tracks operate independently. Ozempic is not covered for weight loss under Medicare Part D — off-label weight-loss use is statutorily excluded.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: Wellcare's commercial enrollment is limited. Where a Wellcare commercial plan exists, Ozempic is covered for type 2 diabetes with prior authorization and metformin step-therapy; not covered for off-label weight loss. Commercially insured T2D patients may be eligible for the NovoCare Ozempic Savings Card ($25 per fill, max $150 per 28-day supply) — verify eligibility on NovoCare.com. ACA/Individual: limited Wellcare ACA presence; covered for T2D with PA where offered. Medicaid: Wellcare operates Medicaid managed-care organizations across multiple states. Ozempic is covered for type 2 diabetes at nominal Medicaid cost-share ($0–$4 typical) per state preferred drug list with PA and step therapy. Not covered for off-label weight loss on any state Medicaid PDL. Verify on your state-specific Wellcare Medicaid plan drug list or call member services.
The 3 boxes you must tick to get approved
Commercial plans that will consider Ozempic require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 3 requirements selected. Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Ozempic actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$1,028/month (Novo Nordisk published pricing, ~$1,027.51 for the 0.25/0.5 mg pen). NovoCare self-pay: ~$199/month intro price (first two fills through December 31, 2026), then ~$349/month (0.25/0.5/1 mg) or ~$499/month (2 mg).
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D: cost-share depends on plan tier and benefit phase; the $2,100 Part D OOP cap limits total 2026 beneficiary exposure. IRA Maximum Fair Price of $274/30-day applies from January 1, 2027 for Medicare patients. Medicaid: $0–$4 nominal for T2D use. Commercial: varies by plan tier — verify on Wellcare plan drug list.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare Ozempic Savings Card: commercially insured T2D patients may pay as little as $25 per fill (max $150 per 28-day supply). Not available to Medicare, Medicaid, VA, DoD, or TRICARE beneficiaries. For weight-loss seekers who need semaglutide without insurance coverage, see the Curex compounded semaglutide offer below.
Reduced copay through the assistance program, where eligible.
All figures are estimates — verify exact cost-share with Wellcare member services or your plan drug list. Tier placement and copay vary across Wellcare's Medicare Part D and Medicaid plans by state.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Look up Ozempic on your Wellcare plan drug list
Log in to your Wellcare member account at wellcare.com and use the drug-lookup tool to confirm Ozempic is on your specific plan's formulary, its tier, and any prior-authorization or step-therapy requirements. Formulary details vary by state and plan type (Part D vs. Medicaid MCO).
- 2
Confirm prior-authorization criteria with your prescriber
Ask your prescriber to initiate the PA through Wellcare. The submission typically requires: a documented T2D diagnosis (ICD-10 E11.x), evidence of metformin use or a documented reason you cannot take it, and — on some plans — documentation of an additional prior oral agent. The clinical indication must be T2D, not weight management.
- 3
Check 2027 IRA pricing and OOP cap impact
If you are on Medicare Part D, note that the IRA Maximum Fair Price of $274/30-day for semaglutide takes effect January 1, 2027 — a meaningful reduction from current cost-share. Until then, the $2,100 OOP cap limits 2026 exposure. Call Wellcare member services at the number on your ID card to get a personalized cost estimate for the current plan year.
Options if Wellcare won't cover Ozempic
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Rybelsus (oral semaglutide)
Oral semaglutide for type 2 diabetes. Also subject to the IRA Maximum Fair Price of $274/30-day effective January 1, 2027. Coverage and tier vary by Wellcare plan — verify on the plan drug list.
Jardiance (empagliflozin)
SGLT-2 inhibitor commonly used as a step-therapy oral agent before GLP-1 approval. Often on a preferred or non-preferred brand tier on Wellcare formularies — lower cost-share than Ozempic in many plans.
Metformin (generic)
Universally covered at Tier 1 on Wellcare Part D and Medicaid plans, typically at $0–$4 copay. Required as step therapy before Ozempic PA approval in most plans.
Compounded semaglutide (weight-loss seekers only)
For patients seeking semaglutide for weight management — not T2D — who are denied under Wellcare, compounded semaglutide from $49/mo is available at getcurex.com/cl/glp without insurance. See the Curex offer section below for full disclaimers.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
No. Wellcare does not cover Ozempic for weight loss under any line of business. Ozempic holds FDA approval only for type 2 diabetes glycemic control, cardiovascular risk reduction in T2D patients with known heart disease, and CKD progression in T2D patients — not for weight loss. Off-label weight-loss use is not a covered indication on Wellcare Medicare Part D, Medicaid, or any other Wellcare plan. Patients seeking semaglutide for weight management are typically denied and should explore other options.
Yes, Wellcare Medicare Part D covers Ozempic for type 2 diabetes with prior authorization. Your prescriber must submit a PA documenting your T2D diagnosis and evidence of metformin step-therapy (or a documented reason you cannot take metformin). Some Wellcare Part D plans require an additional oral agent trial. Tier placement and cost-share vary by plan — confirm on your specific Wellcare plan drug list or call member services.
No, if you are enrolled in Wellcare Medicare or Medicaid. Federal anti-kickback rules prohibit Medicare and Medicaid beneficiaries from using manufacturer savings cards, including the NovoCare Ozempic Savings Card. Commercially insured T2D patients on a Wellcare commercial plan may be eligible for the card ($25/fill, max $150/28-day supply) — verify eligibility at NovoCare.com. Wellcare's Medicare and Medicaid enrollment is its primary business, so most Wellcare members cannot use this card.
In 2026, your Ozempic cost-share under Wellcare Part D depends on its tier and your plan's benefit structure, but total annual out-of-pocket spending is capped at $2,100 under the Medicare Part D cap. Starting January 1, 2027, the IRA Maximum Fair Price for semaglutide (Ozempic/Rybelsus/Wegovy combined) drops to $274 per 30-day supply — a 71% reduction from the CY2024 list price of approximately $959. A separate most-favored-nation pricing track aims for $245/month with a $50 copay; the two tracks operate independently. Contact Wellcare member services for a personalized cost estimate.
Wellcare Part D and Medicaid plans near-universally require documented metformin use as the first step — or a documented medical reason why metformin is contraindicated or not tolerated. Some Wellcare plans additionally require a sulfonylurea or other oral antidiabetic agent trial. A1c thresholds are cited in secondary sources but vary by plan and are not confirmed in a single primary Wellcare formulary document. Ask your prescriber to review your plan's specific PA criteria before submitting the authorization.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreInsurance won't cover Ozempic for weight loss — here's a path that doesn't need it
You just saw how tangled Ozempic coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Ozempic. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Ozempic and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Wellcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Ozempic and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.